3171 results for «280»
3171 results
New horizons in structural heart disease therapy - Cutting-edge stroke prevention devices: WATCHMAN × SENTINEL
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the advances in stroke prevention for patients undergoing TAVI with atrial fibrillation, focusing on left atrial appendage closure (LAAC) and cerebral protection strategies. It highlights the evolving role of WATCHMAN devices and the SENTINEL Cerebral Protection System, emphasising perioperative stroke risk management...
Protect the brain for TAVI - True potential of SENTINEL Cerebral Protection System
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the critical role of cerebral protection during TAVI procedures by focusing on the SENTINEL Cerebral Protection System. It reviews trends in the United States and Japan, presents clinical outcomes one year post-introduction in Japan, and examines key clinical trials through a meta-analysis comparing...
Mastering techniques from basic to complex - Tips and tricks for advanced mitral TEER: anatomy and imaging
13 Feb 2026 – From PCR Tokyo Valves 2026
Advance your expertise in mitral TEER by gaining anatomical insights, understanding device interaction with native valve structures, and learning to prevent and manage procedural complications through case-based imaging and live assessments.
Mastering techniques from basic to complex - Tricuspid TEER fundamentals
13 Feb 2026 – From PCR Tokyo Valves 2026
Gain foundational knowledge in tricuspid TEER by understanding anatomical criteria for patient suitability, key procedural steps, and device techniques, enhanced by simulation-based procedural training.
Getting ready for tricuspid TEER: key steps in building a successful programme
14 Feb 2026 – From PCR Tokyo Valves 2026
Prepare to establish a successful tricuspid TEER programme by understanding essential components such as systematic echocardiographic and clinical assessments for patient selection, procedural fundamentals, and programme development supported by clinical evidence.
Patient selection for tricuspid TEER in 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on optimizing patient selection for tricuspid transcatheter edge-to-edge repair (TEER) in 2026. It integrates anatomical, haemodynamic, and clinical criteria to identify ideal candidates, explores evolving treatment boundaries between TEER, transcatheter tricuspid valve replacement (TTVR), and medical management, and applies evidence from key trials...
Procedural optimisation for enhanced acute and long-term outcomes
14 Feb 2026 – From PCR Tokyo Valves 2026
This session emphasizes procedural optimization in TAVI to enhance both acute and long-term outcomes. It highlights critical factors such as valve sizing, expansion, implantation depth, and commissural alignment. Practical techniques for pre- and post-dilatation alongside commissural alignment are demonstrated through real cath lab cases, underscoring their...
Team approach to structural heart disease: how to handle unexpected situations
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the multidisciplinary team approach to managing structural heart disease, focusing on responses to unexpected intraoperative and postoperative situations. It features real-world experiences from a TAVI radiologic technologist, clinical engineer, TEER sonographer, and TEER nurse, emphasizing their respective roles in addressing intraoperative events, sudden...
Coronary sinus reducer for microvascular angina
28 Feb 2020
A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...
A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
27 Oct 2025
Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.
Author
The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone versus placebo in patients with myocardial infarction
18 Nov 2024
Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.
Author
